Rationalisation of Polypharmacy by the RASP-instrument and Discharge Counselling of Geriatric Inpatients

NCT05816967 | Withdrawn

• 1 other identifier: S59694
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Systematic evaluation of polypharmacy in geriatric patients, through a validated list by a clinical pharmacist. The goal is reduction of potentially inappropriate medications (PIMs). A brief counseling session with the patient and/or his/her caregiver will be part of the intervention.

Conditions

Polypharmacy

Outcome Measures

Primary Outcomes (2)

• Acceptance rate of the pharmacotherapeutic recommendations, provided by the clinical pharmacist by the general practitioner.

  Acceptance rate of the pharmacotherapeutic recommendations, provided by the clinical pharmacist by the general practitioner.

  1 month (30 days) after discharge

• Acceptance rate of the pharmacotherapeutic recommendations, provided by the clinical pharmacist by the general practitioner.

  Acceptance rate of the pharmacotherapeutic recommendations, provided by the clinical pharmacist by the general practitioner.

  3 month (90 days) after discharge

Secondary Outcomes (17)

• Number of drug intakes at discharge versus at admission.

  At discharge from the index hospitalization (as mentioned in the discharge medication scheme) vs on admission (during the first 72 hours of the index hospitalization)

• Number of drugs at discharge versus at admission.

  At discharge from the index hospitalization (as mentioned in the discharge medication scheme) vs on admission (during the first 72 hours of the index hospitalization)

• Number of drugs adapted by the treating physician based on recommendations by the clinical pharmacist that are not included in the RASP list.

  At discharge from the index hospitalization (as mentioned in the discharge medication scheme), compared to the medication list obtained on admission (this is, during the first 72 hours of the hospitalization)

• Difference in number of potentially inappropriate medications identified through the RASP list on admission versus at discharge

  At discharge from the index hospitalisation (as mentioned in the discharge medication scheme) versus on admission (medication list obtained in the first 72 hours) of the index hospitalization

• Number of potentially inappropriate medications on admission, at discharge and at the follow-up moments (1 and 3 months after discharge)

  On admission (medication list obtained in the first 72 hours of the admission), at discharge (as mentioned in the discharge medication scheme), 1 (30 days) month after discharge, 3 months (90 days) after discharge

Study Arms (1)

Intervention group

EXPERIMENTAL

In the monocentric interventional part of the study, the effect of discharge counseling on the acceptance of pharmacotherapeutic recommendations will be evaluated 1 and 3 months after discharge.

Procedure: Medication review and discharge counseling

Interventions

Medication review and discharge counseling PROCEDURE

Medication reconciliation of home therapy will be performed by the clinical pharmacist through a standardized form. Next, the clinical pharmacist will perform a medication review, based on but not limited to the RASP list (Van der Linden 2014). The goal is optimization of therapy. Before discharge the clinical pharmacist will perform a second medication review, together with the treating physician and a medication reconciliation in orde to provide the best possible discharge medication list. The medication list will be provided 3 times: once for the patient and/or his/her caregiver, once for the general practitioner and once for the primary care pharmacist. Finally the clinical pharmacist will have a counseling session with the patient and/or his/her caregiver.

Intervention group

Eligibility Criteria

• Age: 75 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• Informed consent by the patient and/or his/her caregiver
• Admission through the emergency department of patients coming from home or a residential care facility

You may not qualify if:

• Patients not speaking Dutch
• Patients admitted for end of life care
• Patients not taking any drugs on admission

Sponsors & Collaborators

• Universitaire Ziekenhuizen KU Leuven: lead

Study Sites (1)

UZLeuven

Leuven, 3000, Belgium

Location

MeSH Terms

Interventions

Medication Review

Intervention Hierarchy (Ancestors)

Medication Systems; Organization and Administration; Health Services Administration; Patient Care Management

Study Officials

• Julie Hias, Pharm D

  UZ Leuven

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 24, 2022
• First Posted: April 18, 2023
• Study Start: October 1, 2018
• Primary Completion: September 1, 2019
• Study Completion: September 1, 2019
• Last Updated: April 18, 2023

Record last verified: 2023-04

Data Sharing

• IPD Sharing: Will not share

Locations

BE (1)